| 1 | Economic evaluation of Wolbachia deployment in Colombia: A modeling study |
|----|---|
| 2 | |
| 3 | Short title: Economic evaluation of Wolbachia in Colombia |
| 4 | |
| 5 | Donald S. Shepard, PhD ^a |
| 6 | Samantha R. Lee, MS, MA ^a |
| 7 | Yara A. Halasa-Rappel, DMD, PhD ^a |
| 8 | Carlos Willian Rincon Perez, MS ^b |
| 9 | Arturo Harker Roa, PhD ^b |
| 10 | |
| 11 | ^a Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts, USA |
| 12 | ^b School of Government, University of Los Andes, Bogotá, Colombia |
| 13 | |
| 14 | Correspondence: Donald S. Shepard, The Heller School for Social Policy and Management, Brandeis |
| 15 | University, Waltham, MA 02454-9110, USA. Email: shepard@brandeis.edu |
| 16 | |

17 ABSTRACT

18 Background and Aims

| 19 | Wolbachia are bacteria that inhibit dengue virus replication within the mosquito. A cluster-randomized |
|----|---|
| 20 | trial found Wolbachia reduced virologically-confirmed dengue cases by 77% and previous models |
| 21 | predicted Wolbachia to be highly cost-effective in Indonesia, Vietnam, and Brazil. in Colombia, |
| 22 | Wolbachia was introduced in the Aburrá Valley in 2015 and Cali in 2020. To inform decisions about |
| 23 | future extensions, we performed economic evaluations of the potential expansion of Wolbachia |
| 24 | deployments to 11 target Colombian cities. |
| 25 | Methods |
| 26 | We assembled quantities and the distribution by severity of reported dengue cases from Colombia's |
| 27 | national disease surveillance system and the health service provision registry (RIPS). An epidemiological |
| 28 | panel of three experts estimated the shares of non-medical cases and adjustments for under-reporting |
| 29 | and misclassifications. We determined costs (in 2020 US dollars) of treating dengue illness from the |
| 30 | benchmark insurance tariff, RIPS data on treatment services per symptomatic dengue case, and the |
| 31 | national government database for establishing insurance premiums. A cluster randomized trial |
| 32 | quantified the effectiveness of Wolbachia against symptomatic dengue cases. |
| | |

33 <u>Results</u>

Projecting impact over 10 years for Cali, we estimated a net health-sector savings of USD4.95 per
person. We also estimated averting 369 disability-adjusted life years (DALYs) per 100,000 population.
From a societal perspective, at 10 years *Wolbachia* deployment is expected to have highly favorable
benefit-cost ratios, with benefits per dollar invested of \$5.50 in Cali and USD4.68 over all target cities.

38 <u>Conclusions</u>

- 39 Over 10 years, *Wolbachia* is highly beneficial on economic grounds, and almost universally cost saving.
- 40 That is, Wolbachia's savings in health care costs alone would more than offset deployment costs
- 41 nationally and in 9 target cities (those with adjusted annual dengue incidence at least 50/100,000
- 42 population). In these 9 target cities, *Wolbachia* would generate at least USD3.00 in benefits per dollar
- 43 invested, giving substantial confidence that *Wolbachia* deployment would be cost-beneficial in
- 44 Colombia.
- 45
- 46 Key words:
- 47 Dengue, Colombia, *Wolbachia*, Cost-effectiveness analysis, Benefit-cost analysis, Mosquito control

49 Introduction

50 Dengue, responsible for dengue fever and dengue hemorrhagic fever, is the most widespread vector-51 borne virus in the southern hemisphere.[1] Colombia has experienced recent dengue epidemics in

52 2010, 2013, and 2019.[2]

| 53 | Wolbachia are common bacteria that naturally infect fruit flies and many other insects. |
|----|---|
| 54 | Researchers at the World Mosquito Program (WMP) discovered that they could infect Aedes aegypti |
| 55 | mosquitoes with these bacteria[3] and that dengue, chikungunya and Zika viruses are then less able |
| 56 | to replicate within the insects, thereby inhibiting the transmission of these mosquito-borne |
| 57 | infections.[4] To use this method for disease control, governments, communities, and international |
| 58 | organizations (e.g., the WMP) partner to grow mosquitoes infected with Wolbachia in insectaries and |
| 59 | then deploy eggs or adult mosquitoes to establish the bacteria in the local mosquito population. |
| 60 | Wolbachia-infected mosquitoes transmit the bacteria through their eggs to the next generation. This |
| 61 | approach is termed the "replacement" strategy, as it tends to replace wild mosquitoes by Wolbachia- |
| 62 | infected ones. Thus, the establishment of Wolbachia becomes a sustainable and often long-term |
| 63 | control mechanism at that site. The replacement approach was first applied near Cairns, Australia. |
| 64 | Over a decade after initial deployment, mosquitoes there remain infected with the bacteria, |
| 65 | supporting the long-term viability of the approach.[5] The replacement approach is being applied in |
| 66 | countries in the Americas, Asia, and Oceania.[6] |
| 67 | Under a different approach, the <i>Wolbachia</i> suppression strategy, Singapore releases only male |
| - | |

68 *Wolbachia* infected mosquitoes.[3] When these mosquitoes mate with wild mosquitoes, the eggs do 69 not hatch, thereby reducing the number of potentially disease-carrying insects. While experience to 70 date has found this approach efficacious, the need for annual releases makes the suppression

approach more costly but potentially economically viable in this high-income country.[7] The

remainder of this paper considers only the replacement approach.

73 A landmark cluster-randomized trial in Yogyakarta, Indonesia found that the replacement 74 strategy reduced all virologically-confirmed symptomatic dengue cases by 77.1% and hospitalized 75 cases by 86.2% under the original protocol analysis.[8] A reanalysis that corrected for the attenuation 76 due to border crossing by humans and mosquitoes raised the estimated efficacy against dengue cases 77 to 82.7%.[9] A subsequent cluster randomized trial is underway in Belo Horizonte, Brazil. A guasi-78 experimental study from Niterói, Brazil found that Wolbachia reduced incidence of dengue by 69%, of 79 chikungunya by 56%, and of Zika by 37%.[10] Research in Rio de Janeiro has shown that the 80 technique is generally robust. Even in neighborhoods where *Wolbachia* coverage was low, such in

81 *favelas* where access was difficult, dengue infections were still reduced by 38% and chikungunya by

82 10%.[11]

72

83 In Colombia, pilot Wolbachia releases began in the city of Bello in 2015 and were expanded in 2017 to city-wide deployments throughout Medellín, Itagui and Bello in the Aburrá Valley. An 84 85 evaluation based on routine disease surveillance data reported reductions in notified dengue 86 incidence of 95% to 97% in the three cities following Wolbachia introduction, compared to the prior 87 decade; a parallel case-control study in Medellín also showed significantly lower dengue incidence in Wolbachia-treated neighborhoods compared to untreated ones.[12-15] Deployment progressed to 88 89 Cali, with phased releases since 2020. In May 2023, Cali's coverage reached 50% and the 90 departmental and municipal governments announced the expansion of Wolbachia to Yumbo 91 municipality, 13 km northeast of Cali.[16]

| 92 | Wolbachia is predicted to be a highly cost-effective intervention for controlling mosquito- |
|---------------------------------|--|
| 93 | borne illnesses, especially when released in high-density urban areas. In Indonesia, Wolbachia was |
| 94 | projected to have a cost-effectiveness ratio in US dollars (USD) of USD1500 per disability-adjusted life |
| 95 | year (DALY) averted, offsetting much of the costs to the health system and to society with benefit- |
| 96 | cost ratios ranging from 1.35 to 3.40.[17] In Vietnam, another study found the technology similarly |
| 97 | cost effective based on the 10-year time horizon, and cost-saving at the 20-year time horizon.[18] A |
| 98 | simulation across seven Brazilian cities also found Wolbachia cost-effective across all 7 cities |
| 99 | modeled, though not cost saving[19] in 2 of the 7 cities. In Suva, Fiji, a much smaller city, Wolbachia |
| 100 | was acceptably cost-effective, but in Port Vila, Vanuatu, the relatively small target population and |
| 101 | lower population density would not make the approach cost-effective there.[20] A simulation for |
| 102 | Thailand suggested that Wolbachia combined with vaccination could be cost-effective.[21] |
| | |
| 103 | To inform decision making within Colombia, we modeled the large-scale implementation of the |
| 103 104 | To inform decision making within Colombia, we modeled the large-scale implementation of the <i>Wolbachia</i> replacement strategy for controlling dengue in 11 target Colombian cities. Here we |
| | |
| 104 | Wolbachia replacement strategy for controlling dengue in 11 target Colombian cities. Here we |
| 104 105 | Wolbachia replacement strategy for controlling dengue in 11 target Colombian cities. Here we |
| 104 105 106 | <i>Wolbachia</i> replacement strategy for controlling dengue in 11 target Colombian cities. Here we present the resulting cost-effectiveness and benefit-cost analyses. |
| 104 105 106 107 | Wolbachia replacement strategy for controlling dengue in 11 target Colombian cities. Here we present the resulting cost-effectiveness and benefit-cost analyses. |
| 104 105 106 107 108 | Wolbachia replacement strategy for controlling dengue in 11 target Colombian cities. Here we present the resulting cost-effectiveness and benefit-cost analyses. Methods Framework |

112 Colombia's reported dengue cases from 2010 through 2019. We conducted economic analyses for

- each of these target cities. Colombia's capital and largest city, Bogotá, is virtually free of dengue due
- to its high altitude, so it was not a target city.

| 115 The analyses were done | by city, as costs, imp | pacts, and funding decisions lie partly | / at the |
|----------------------------|------------------------|---|----------|
|----------------------------|------------------------|---|----------|

- 116 municipal level. Our analysis began by estimating the current burden of dengue-related illness in
- each of these target cities in terms of average annual numbers of cases, health care costs, and loss of
- health from non-fatal dengue cases. We then estimated the expected gains from *Wolbachia* based on
- the Yogyakarta cluster randomized trial. Next, we examined the cost of implementing *Wolbachia*
- 120 based on the WMP's recent Colombian projects. Finally, we calculated cost-effectiveness and benefit-
- 121 cost ratios showing the ratio of predicted health care gains to estimated costs by city.
- 122 Parameters
- 123 Table 1 provides the necessary national parameters for the economic analysis with monetary amounts
- 124 in 2020 USD.

125

126 Table 1. National Parameters

| Label | Parameter | Value |
|-------|--|----------|
| | | |
| P1 | Average health system cost per dengue case in 2019-20 for cases treated in the | \$202.11 |
| | medical sector, USD | |
| P2 | Average health system cost per dengue case in 2019-20 for cases treated in the | \$116.90 |
| | medical and non-medical sectors combined, USD | |

| Р3 | Estimated cost of Wolbachia per km ² in target cites in Colombia, USD | \$87,625 |
|-----|--|----------|
| Р4 | Estimated % savings in conventional vector control spending, year 1, | 0% |
| Р5 | Estimated % savings in conventional vector control spending, year 2 | 20% |
| P6 | Estimated % savings in conventional vector control spending, year 3 | 30% |
| Ρ7 | Estimated % savings in conventional vector control spending, year 4 | 40% |
| Р8 | Estimated % savings in conventional vector control spending, years 5+ | 50% |
| Р9 | Efficacy of Wolbachia intervention (%), year 1 from date of deployment | 37.5% |
| P10 | Efficacy of Wolbachia intervention (%), years 2+ from date of deployment | 75.0% |
| P11 | Efficacy of Wolbachia intervention (%), 10-year average | 71.3% |
| P12 | Annual discount rate for costs and health effects | 3% |
| P13 | DALY/dengue case | 0.0476 |
| P13 | Share of Wolbachia deployment cost that is incurred in year 1 | 100% |
| P15 | Share of Wolbachia deployment cost needed for long term monitoring, year 2+ | 1% |
| P16 | Cumulative present value factor over 10 years using P12 | 8.53 |
| P17 | Colombia GDP/capita (2020), World Bank, market prices, USD | \$5,312 |
| P18 | Share of dengue cases correctly reported in surveillance system | 29% |

P19 Share of *Wolbachia* costs for preparation, before deployment

20.54%

| 127 | Legend: DALY=disability-adjusted life year; GDP=gross domestic product; km=kilometers; SOAT=Seguro |
|-----|--|
| 128 | Obligatorio para Accidentes de Tránsito (Compulsory Insurance for Traffic Accidents), the reference |
| 129 | prices used by Colombian insurers; USD=United States dollars. Monetary amounts are in 2020 USD at |
| 130 | market exchange rates. Sources: For P1 and P2, items were available only for 2019; these were adjusted |
| 131 | for inflation and changes in exchange rates, giving virtually identical values in 2020 USD as of 2019. For |
| 132 | P3, cost data were provided by the WMP based on its budget projections. They apply to all target cities |
| 133 | except Cali. For Cali, where Phase I implementation had been conducted, delays due to interruptions |
| 134 | from the COVID-19 pandemic increased costs. The COVID interruption raised the projected cost per |
| 135 | km2 for Cali across all phases to \$96,698. |
| | |
| 136 | For P12, we relied on a leading textbook on economic evaluation in health.[22] For P13, the disease |
| 137 | burden per case of dengue is the sum of its morbidity and mortality components. The morbidity |
| 138 | component was 0.032.[23] The mortality component was calculated first by dividing the average |
| 139 | number of deaths due to dengue between the years 2012 through 2018 by the average incidence for |
| 140 | these same years. The resulting weighted average case-fatality rate was 6.05 $	imes$ 10 ⁻⁴ . Based on an |
| 141 | estimated 50 years of remaining life (as young adults are the median age of dengue fatalities) and the |
| 142 | widely recommended discount rate of 3%, the discounted remaining life was calculated using the |
| 143 | following formula: Discounted remaining life = [1 - (1 + P12) ⁻⁵⁰] /P12 = 25.73. The mortality component |
| 144 | was 0.0156 DALYs (i.e. 6.05 × 10^{-4} x 25.73). The overall burden per case was 0.0476 DALYs (i.e., 0.032 + |
| 145 | 0.0156). |

P16, the cumulative present value factor, was calculated with the Excel present value function (PV) using
P12 and a time horizon of 10 years, i.e., PV(P12,10,-1) equals 8.53; P17 is from the World Bank[24]; all
other items are based on the authors' calculations.

149 Disease burden of dengue

150 The disease burden of dengue in a specified geographical area in a year is best conceptualized as the 151 product of its number of dengue cases times the disease burden per case. Global research has found 152 that a substantial share of dengue cases are treated outside the formal health sector, and thus not 153 captured in existing databases.[25] To apply this concept to Colombia, we assessed the breakdown of 154 dengue cases by severity and reporting status. We relied on the expertise of three epidemiologists: Luz 155 Inés Villarreal Salazar (independent consultant in Colombia), Carlos Willian Rincon (University Los 156 Andes), and Maria Patricia Arbelaez Montoya (World Mosquito Program, Colombia). We adjusted for 157 underreporting of the number of dengue cases using an adjustment factor derived from *el Sistema* 158 Nacional de Vigilancia en Salud Pública (SIVIGILA) [the National Public Health Surveillance System] and Registro Individual de Prestación de Servicios de Salud Municipio de Envigado (RIPS) [Individual Registry 159 160 of Provision of Health Services Municipality of Envigado].

To adjust for the fact that routine programs often have fewer resources and less intensive supervision than research trials, we rounded down the per-protocol efficacy from the Indonesian cluster randomized trial.[8] We projected that the *Wolbachia* program in Colombia will result in a 75% reduction in dengue cases once *Wolbachia* is stably established in the mosquito population--the second year of implementation onwards based on projected time for deployment. Projecting a linear increase from zero to complete establishment of *Wolbachia* over the first year of implementation, we estimated a 37.5% reduction in dengue cases overall in the first year.

168 Current cost of a dengue episode

| 169 | The aggregate cost of dengue is the product of the average cost per case times the number of cases. We |
|-----|---|
| 170 | used two approaches to estimate the cost of a dengue case in Colombia. Under our main approach, the |
| 171 | average direct cost of a dengue case treated in the formal health system in 2019 was estimated using |
| 172 | the tariffs to pay treatment costs from transit accidents, Seguro Obligatorio para Accidentes de Tránsito |
| 173 | (SOAT) [Compulsory Insurance for Traffic Accidents]. The SOAT tariffs also serve as reference prices in |
| 174 | payment negotiations between insurers and providers. While actual payment rates from other insurers |
| 175 | are not publicly available, experts believe that actual payment rates likely average the SOAT rates. |
| 176 | Anecdotal reports suggest that in rural areas, where providers are few, providers are paid above the |
| 177 | SOAT rates, whereas in urban areas, where providers are numerous, payers can negotiate discounts |
| 178 | below the SOAT rates. |
| 179 | We converted the SOAT amounts in Colombian pesos to US dollars at the average exchange rate |

for the years 2015-2020.[26] For most curative services in the health care system, RIPS provides a national claims system that captures the health care provided to the insured population by diagnostic codes, care provided, and care setting. The data include the number of consultations and procedures used, emergency room visits, and hospitalizations. RIPS categorized dengue cases as classic dengue and severe dengue. For verification we used the *Suficiencia* [Sufficiency] database, which provides service payments for calculating the *Unidad de Pago por Capitación (UPC)* [Capitation Payment Unit] and premium information.[27]

Using the SOAT tariff, we derived the cost per case through stratification by the severity of
 dengue and calculated a weighted average based on the estimated share of dengue cases by severity. To
 reflect the fact that a number of non-hemorrhagic (classical) cases were hospitalized, we stratified by

190 severity category instead of treatment setting for consistency among data sources. To report the cost of 191 all types of dengue cases in Colombia from the health system perspective, we adjusted for cases treated 192 outside the health care system. To estimate the economic cost, we incorporated both the cost of cases 193 treated outside the health care system and direct and indirect household expenditures during a dengue 194 episode. We then analyzed the RIPS claims data to derive the average cost of a non-fatal dengue case 195 for the years 2015 through 2020 and reported the average 5-year cost per case based on the severity of 196 dengue, i.e., severe and non-severe dengue. The claims data included the total number and cost of 197 dengue health care services based on the care setting: consultations, procedures, emergencies, and 198 hospitalizations.

To validate our SOAT-based estimate of the healthcare cost per dengue case, we used aggregate data (see Supporting Information S2 Text, Supporting Information S3 Table and Supporting Information S4 Table). [28-33] This aggregate approach, termed macro-costing, used an empirical bed-day equivalent factor of 0.32 of an ambulatory visit compared to an inpatient day[32] and the average cost of a hospitalization and an ambulatory visit. Macro-costing remained a secondary estimate, however, as its applicability rested on the assumption that visits and hospitalizations for dengue consumed the same resources, on average, as visits and hospitalizations for all causes combined.

206 Disease burden of dengue per case

Based on the calculation provided for discounted remaining life, the years of life lost and years lost to
disability per case are 0.0156 and 0.0320,[23] corresponding to shares of 33% and 67%, respectively.
The sum of these two metrics comprised the total disease burden per dengue case of 0.0476 DALYs.

210 Cost of Wolbachia deployment

To estimate the cost of the *Wolbachia* program in the 11 target cities in Columbia, we started by analyzing the program budget for Cali. The budget covered two programmatic phases, with each phase divided into three stages: prepare, release, and short-term monitoring (STM). The budget covered the administrative and management cost, communication, community engagement, data management, diagnostic, monitoring, mosquito rearing, the release of the *Wolbachia* mosquitoes, surveillance, site start-up, project oversight, and indirect (facilities and administrative) costs.

The preparation stage lasted 12 and 6 months for phases 1 and 2 of the Cali program, respectively; release stages each took 6 months, and the STM stage was 12 months. Initially, the WMP projected that implementation of the *Wolbachia* program would take three years per city. After further review, however, WMP officials and the authors agreed that expansion of the existing program to additional cities in Colombia, and likely in other countries in a scale-up phase, could be achieved with an accelerated timeline and reduced the projected duration.

223 Based on the shortened timeframes, we reduced the durations of projected staff 224 requirements. We estimated the indirect cost of the Wolbachia program at 15% of direct costs. This is 225 the maximum global rate allowed to grantees by the Bill & Melinda Gates Foundation, [28] a major 226 sponsor of Wolbachia development. Brandeis researchers also reduced the estimated time needed for 227 preparation, release, and long-term monitoring from 30 months to 15 months. Both adjustments 228 reduced the overall projected per square kilometer (km²) cost of the Wolbachia program. To estimate 229 the overall cost of the program in the 11 target cities, we made the preceding two adjustments to the 230 budgeted cost of Cali phase 2 deployments to derive an adjusted cost per km² (parameter P5). WMP 231 estimated the projected release area (km²) in each target city, including all built-up areas and excluding

| 232 | public spaces, parks, and empty spaces. This area was multiplied by the adjusted cost per km ² |
|-----|---|
| 233 | (parameter P3) to estimate the cost of implementation in the rest of Cali and the 10 other target cities. |
| 234 | Our cost projections generated both best estimates and confidence bounds. The uncertainty |
| 235 | reflected alternative estimates of the size of the deployment needed and the cost adjustment |
| 236 | attributable to the pause in Cali phase 1 deployment due to the COVID-19 pandemic. The |
| 237 | implementation costs occur primarily during the first and second years of release and STM, with an |
| 238 | estimated 1% of the initial spending needed annually for long-term monitoring from the second year |
| 239 | onward. |

240 Economic appraisal

241 We calculated the medical cost offsets from dengue cases averted each year as the cost per 242 symptomatic case times the baseline average number of such cases times the fraction averted in each 243 city year. Although some health economists disagree with discounting future health effects, [34] a 244 leading textbook and Colombia-specific guidelines recommend that future costs and health benefits 245 should be discounted.[22, 35] We calculated the present value of the *Wolbachia* program and all cost 246 offsets in each city over a ten-year time horizon with a discount factor from P12. The vector control 247 offset was calculated through percentagewise cost savings in parameters P4 through P8. The medical cost offset comprises the estimated reduction of cases over the ten-year time horizon. The present 248 249 value of these offsets was calculated as the annual full-deployment result time the cumulative present 250 value factor for ten years (parameter P16) less an adjustment for the smaller effectiveness in year 1. If 251 we had decided not to discount, then the present value costs would have changed little, but the 252 present value of health impacts would have been substantially higher.

253 To value the indirect benefits (gains in quality and length of life), we needed to assign an 254 economic value to a year of good health—averting a DALY or gaining a Quality-adjusted Life Year 255 (QALY). This valuation is equivalent to setting a threshold value for determining the cost-effectiveness 256 of a health intervention. In 2001, the World Health Organization's Macroeconomic Commission on 257 Health recommended thresholds of 1 and 3 times a country's per capita Gross Domestic Product (GDP) 258 for an intervention to be "very cost-effective" or "cost effective," respectively.[36] Subsequently, WHO 259 officials recommended finding evidence-based thresholds and incorporating fairness and affordability 260 into the decision process.[37] Economic theory suggests that evidence consider the public's willingness 261 to pay (WTP) to avert one DALY or gain one QALY.[22]

262 To apply this concept, we searched PubMed for studies on WTP in Colombia. The one study we 263 found, modeling chemotherapy for lung cancer, did not present an empirical estimate, but simply 264 selected a value of US\$17,656, three times Colombia's then GDP per capita.[38] A wider search, a 265 systematic global review of WTP studies, found a median value for upper-middle income countries (the 266 relevant category for Colombia) of US\$5,936, with an interquartile range of US\$7,233.[39] However, 267 none of the included studies was conducted in Colombia and upper-middle income countries span a 268 wide range of per capita GDP. However, in 2023, an empirical approach was published for WTP 269 thresholds and applied to 174 countries.[40] It included Colombia. Based on national data rather than 270 survey responses, it calculated national WTPs based on the country's changes in life expectancy and 271 health expenditures. This approach found that Colombia's WTP per QALY gained (equivalent to a DALY 272 averted) was 0.75 times its per capita GDP in 2019. An independent commentary noted the many 273 advantages of this approach.[41] Like that in most upper-middle income countries, Colombia's WTP as 274 a proportion of per capita GDP fell in the range of 0.5 to 1.0. Applying Colombia's ratio, we valued each

- 275 DALY in our target year (2020) in Colombia as 0.75 times that year's per capita GDP. That is, each DALY
- averted through reduced dengue had an economic value of USD3,984.
- We calculated each city's benefit-cost ratio as its total economic benefits (including the
 economic value of good health) divided by the cost of the deployment. If this ratio exceeded 1.0, *Wolbachia* was considered a favorable economic investment. The incremental cost-effectiveness ratio
 (ICER) is the net present value cost of the *Wolbachia* program divided by its present value health gain in
 DALYS. A positive ICER below USD3,984 (0.75 times Colombia's per capita GDP[20] of USD5,312)
 indicates that the intervention is cost-effective. A negative ICER indicates that the replacement
 strategy is cost saving in that city, i.e., exceptionally cost-effective.
- 285 Results

286 <u>Current cost per case of dengue</u>

The epidemiological panel provided the following five categories for the distribution of dengue cases in Colombia by severity and reporting to SIVIGILA: (1) 2% are severe cases and correctly diagnosed and reported to SIVIGILA, (2) 27% are non-severe dengue (including those with and without warning signs) and correctly reported to SIVIGILA, (3) 11% are non-severe dengue, diagnosed by medical providers but not reported to SIVIGILA due to time and administrative barriers, (4) 20% are non-severe dengue cases that are misdiagnosed (e.g., diagnosed as a non-specific viral fever), and (5) 40% are mild and do not interact with the formal healthcare system (i.e. home treatments).

294 Supporting Information S5 Table presents the average cost of a dengue case by severity and 295 the proportion of dengue cases treated by setting. Only 29% of dengue cases are reported, almost all of

- which are non-severe dengue. Based on SOAT tariff, we estimated the healthcare cost of care for cases
- within the medical system as USD406.37 for a severe case (constituting 6.45% of medical cases) and
- 298 USD188.02 for a non-severe medical dengue case (constituting 93.55% of medical cases). The weighted
- average healthcare cost per medical case was USD202.11 and USD1.50 for a non-medical dengue case.
- 300 The societal cost per case averaged USD151.96, comprised of healthcare costs (averaging USD116.90)
- and indirect costs (averaging USD35.06).

302 Economic results in target cities

- 303 Table 2 displays the analytic results of *Wolbachia* releases for each target city and the national total
- 304 (sum of all target cities). Table 3 presents the costs and benefits as rates per person covered and gives
- final economic results. All benefit cost ratios are favorable or highly favorable, ranging from 1.39 to
- 306 8.85.

| | | | Adjusted | | | | | | |
|------|---------------|------------|--------------|-------------|--------------------|----------------------|---------------------------|---------------------------|--------------------|
| | | Adjusted | release area | Initial | | | | | |
| | | population | dengue cases | Wolbachia | PV Wolbachia | PV vector | | | |
| | | in release | (including | deployment | program | control | PV medical | | PV |
| Rank | Municipality | area | unreported) | costs | costs ^a | offsets ^a | cost offsets ^a | PV net costs ^a | DALYs ^a |
| | | | | | | | | | |
| 1 | Cali | 2,217,961 | 27,649 | \$8,973,571 | \$9,672,263 | \$563,261 | \$20,086,318 | -\$10,977,315 | 8,174 |
| | | | | | | | | | |
| 2 | Ibagué | 503,745 | 10,342 | \$2,269,484 | \$2,446,189 | \$238,873 | \$7,512,810 | -\$5,305,494 | 3,057 |
| | | | | | | | | | |
| 3 | Villavicencio | 506,145 | 10,161 | \$2,506,072 | \$2,701,197 | \$309,493 | \$7,381,782 | -\$4,990,078 | 3,004 |
| | | | | | | | | | |
| 4 | Cúcuta | 759,395 | 9,739 | \$4,363,719 | \$4,703,483 | \$1,195,491 | \$7,075,123 | -\$3,567,131 | 2,879 |
| | | | | | | | | | |
| 5 | Bucaramanga | 604,186 | 9,540 | \$1,989,085 | \$2,143,957 | \$803,501 | \$6,930,606 | -\$5,590,150 | 2,821 |
| | - | | | | | | | | |
| 6 | Neiva | 343,194 | 7,035 | \$1,857,647 | \$2,002,286 | \$159,430 | \$5,110,385 | -\$3,267,529 | 2,080 |
| | | | | | | | | | |

Table 2. Aggregate costs and DALYs for target cities following the start of Wolbachia releases

| 7 | Barranquilla | 1,296,471 | 6,015 | \$5,783,242 | \$6,233,532 | \$226,281 | \$4,370,044 | \$1,637,207 | 1,778 |
|-----|--------------|-----------|--------|--------------|--------------|-------------|--------------|---------------|--------|
| 8 | Valledupar | 477,763 | 3,937 | \$2,234,434 | \$2,408,410 | \$295,246 | \$2,860,029 | -\$746,866 | 1,164 |
| 9 | Armenia | 300,785 | 4,100 | \$1,253,036 | \$1,350,598 | \$124,653 | \$2,978,651 | -\$1,752,705 | 1,212 |
| 10 | Pereira | 404,270 | 3,262 | \$1,524,673 | \$1,643,386 | \$127,747 | \$2,369,401 | -\$853,762 | 964 |
| 11 | Cartagena | 926,747 | 2,460 | \$3,864,257 | \$4,165,132 | \$1,103,887 | \$1,786,889 | \$1,274,356 | 727 |
| ALL | National | 8,340,662 | 94,239 | \$36,619,221 | \$39,470,433 | \$5,147,863 | \$68,462,037 | -\$34,139,468 | 27,862 |
| | _ | | | | | | | | |

^a 10-year present values.

Note: DALYs=disability adjusted life years; PV=present value over 10 years discounted using P12; population in the release areas derived by the World Mosquito Program based on analyses of population density; monetary amounts are in 2020 US dollars. Cities are ranked in decreasing number of average annual dengue cases from 2010 through 2019 (see Supporting Information Table S1). Table 3. Ratios for target cities following the start of Wolbachia releases

| | | | | PV | | | | | |
|------|---------------|------------|----------------|---------|-------------|--------------|-------------|------------|----------|
| | | PV | PV | medical | | | | | |
| | | Wolbachia | conventional | care | | PV overall | | | |
| | | deployment | vector control | offsets | PV indirect | gross | PV DALYs | | |
| | | costs per | offsets per | per | benefits | benefits per | averted per | | |
| | | person | person | person | per person | person | 100,000 | Benefit- | |
| Rank | Municipality | covered | covered | covered | covered | covered | population | cost ratio | ICER |
| | | | | | | | | | |
| 1 | Cali | \$4.36 | \$0.25 | \$9.06 | \$14.68 | \$23.99 | 369 | 5.50 | -\$1,343 |
| 2 | Ibagué | \$4.86 | \$0.47 | \$14.91 | \$24.18 | \$39.57 | 607 | 8.15 | -\$1,735 |
| 3 | Villavicencio | \$5.34 | \$0.61 | \$14.58 | \$23.65 | \$38.84 | 594 | 7.28 | -\$1,661 |
| 4 | Cúcuta | \$6.19 | \$1.57 | \$9.32 | \$15.11 | \$26.00 | 379 | 4.20 | -\$1,239 |
| 5 | Bucaramanga | \$3.55 | \$1.33 | \$11.47 | \$18.60 | \$31.40 | 467 | 8.85 | -\$1,982 |
| 6 | Neiva | \$5.83 | \$0.46 | \$14.89 | \$24.14 | \$39.50 | 606 | 6.77 | -\$1,571 |

| 7 | Barranquilla \$4.81 \$0.17 \$ | | \$3.37 | \$5.47 | \$9.01 | 137 | 1.87 | \$921 | |
|-----|-------------------------------|--------|--------|--------|---------|---------|------|-------|----------|
| 8 | Valledupar | \$5.04 | \$0.62 | \$5.99 | \$9.71 | \$16.31 | 244 | 3.24 | -\$642 |
| 9 | Armenia | \$4.49 | \$0.41 | \$9.90 | \$16.06 | \$26.37 | 403 | 5.87 | -\$1,446 |
| 10 | Pereira | \$4.07 | \$0.32 | \$5.86 | \$9.50 | \$15.68 | 239 | 3.86 | -\$885 |
| 11 | Cartagena | \$4.49 | \$1.19 | \$1.93 | \$3.13 | \$6.25 | 78 | 1.39 | \$1,752 |
| ALL | National | \$4.73 | \$0.62 | \$8.21 | \$13.31 | \$22.13 | 334 | 4.68 | -\$1,225 |

Note: DALYs = disability adjusted life years; ICER=incremental cost-effectiveness ratio; PV=present value over 10 years discounted from P12.

Monetary amounts are in 2020 US dollars. Cities are ranked in decreasing number of average annual dengue cases from 2010 through 2019 (see Supporting Information Table S1). National represents the sum of all target cities.

| 309 | To illustrate our results in greater detail, we have focused on Cali. It was the city with |
|-----|---|
| 310 | the greatest burden in reported dengue cases. After the Aburrá Valley, where Wolbachia had |
| 311 | been deployed previously,[12-15] Cali is the one target city in Colombia in which Wolbachia is |
| 312 | already partly deployed. Fig 1 displays the cumulative projected economic benefits of the |
| 313 | Wolbachia program in Cali by component and time horizon, where time is the number of |
| 314 | completed years since Wolbachia deployment. Wolbachia is projected to replace some |
| 315 | conventional vector control, lower the need for medical care for treating dengue illness, and |
| 316 | create economic value of additional healthy years. The overall economic benefits, the sum of |
| 317 | these components, grows with increasing time horizons to USD42.97 per person covered with a |
| 318 | 20-year horizon. Over this horizon, indirect benefits (the economic value of reduced illness, |
| 319 | USD26.27) are the largest component, followed by medical care offsets (USD16.20), with vector |
| 320 | control offsets as the smallest benefit (USD0.50), |
| 321 | |
| 322 | <insert 1="" about="" fig="" here=""></insert> |
| 323 | |
| 324 | The upper (dashed) line in Fig 2 shows the cost per person of implementing the |
| 325 | Wolbachia program. The cost per person starts in year 0 with 20.54% of initial program costs |
| 326 | (USD0.83) for planning and engagement of residents and local leaders. The remainder of initial |
| 327 | costs occur in year 1, the year in which city-wide releases would occur, bringing initial program |

- 328 costs to USD4.05. Thereafter, annual monitoring occurs, if needed, costing 1% of the initial costs
- 329 annually throughout the remainder of the time horizon. Thus, cumulative Wolbachia
- implementation costs per person rise to USD4.20 through 5 years and USD4.63 through 20 years.

| 331 | Whereas longer time horizons generated substantially larger benefits for each of the economic |
|---|--|
| 332 | benefits, they added very little to the present value of Wolbachia program costs. The lower |
| 333 | (solid) line is the net healthcare cost at each time horizon. In year 0, when there are no offsets, |
| 334 | it is identical to costs of planning and engagement (USD0.83). In year 1, with some conventional |
| 335 | vector control and medical care offsets, net healthcare costs per person covered reached the |
| 336 | maximum (USD3.50). In subsequent years, healthcare offsets exceed the additional vector |
| 337 | control costs. At 4.3 years, Wolbachia becomes cost saving in health care costs. With longer |
| 338 | time horizons, the cost savings continue to grow. Net costs per person become substantial |
| 339 | negative numbers (-USD4.95 and -USD12.08) with the 10- and 20-year horizons, respectively. |
| 340 | |
| 341 | <insert 2="" about="" fig="" here=""></insert> |
| | |
| 342 | |
| 342 343 | Fig 3 shows the summary outcome measures on health (DALYs averted) and economic |
| | Fig 3 shows the summary outcome measures on health (DALYs averted) and economic impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a |
| 343 | |
| 343 344 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a |
| 343 344 345 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a 10-year horizon, the <i>Wolbachia</i> program averts 369 DALYs per 100,000 population with a |
| 343 344 345 346 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a 10-year horizon, the <i>Wolbachia</i> program averts 369 DALYs per 100,000 population with a benefit-cost ratio of 5.50. This highly favorable ratio indicates that every dollar invested |
| 343 344 345 346 347 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a 10-year horizon, the <i>Wolbachia</i> program averts 369 DALYs per 100,000 population with a benefit-cost ratio of 5.50. This highly favorable ratio indicates that every dollar invested generates USD5.50 in economic benefits for the city's residents through better health and |
| 343 344 345 346 347 348 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a 10-year horizon, the <i>Wolbachia</i> program averts 369 DALYs per 100,000 population with a benefit-cost ratio of 5.50. This highly favorable ratio indicates that every dollar invested generates USD5.50 in economic benefits for the city's residents through better health and averting healthcare costs. With a 20-year horizon, these results become almost twice as |
| 343 344 345 346 347 348 349 | impact (benefit-cost ratio) for Cali. Both measures increase with longer time horizons. With a 10-year horizon, the <i>Wolbachia</i> program averts 369 DALYs per 100,000 population with a benefit-cost ratio of 5.50. This highly favorable ratio indicates that every dollar invested generates USD5.50 in economic benefits for the city's residents through better health and averting healthcare costs. With a 20-year horizon, these results become almost twice as favorable, averting 659 DALYs and a benefit-cost ratio of 9.29 to 1. Since the economic benefits |

353

354 <Insert Fig 3 about here>

355

| 356 | Extending these results nationally, Fig 4 presents the benefit-cost ratios for all target |
|-----|---|
| 357 | cities based on the 10-year horizon. Panel A displays the cities in decreasing order. Projections |
| 358 | for all target cities are favorable, as all the ratios exceed 1.00. Cali is close to the national |
| 359 | average. Cartagena is the most marginal in economic terms (ratio 1.39), while Bucaramanga, |
| 360 | with a ratio of 8.85, is almost twice as favorable as the national average. Panel B shows a scatter |
| 361 | plot of these ratios in relation to population density and average annual dengue incidence. |
| 362 | Higher values of both independent variables tend to be associated with higher (more favorable) |
| 363 | benefit-cost ratios. Dengue incidence is the more important factor as it varies 8-fold from the |
| 364 | least to the most affected city. Higher population density, which varies by a factor of 1.7, |
| 365 | contributes marginally to higher ratios. |
| 366 | |
| 367 | <insert 4="" about="" fig="" here=""></insert> |
| 368 | |
| 369 | |

370 Discussion

371 Colombia is hyperendemic with dengue.[2] Accounting for cases treated outside the medical 372 system, misdiagnosed, or otherwise not reported, we concluded that the country's dengue 373 burden is several times greater than official statistics. Our estimates reinforce previous research 374 that Colombia's dengue burden exceeds the global average.[17, 25] 375 If implemented with efficacy mirroring the results from the cluster randomized trial, [8] 376 Wolbachia will substantially mitigate dengue incidence in the target cities in Colombia. These 377 impacts generate highly favorable benefit-cost ratios by helping to avert healthcare and indirect 378 costs. In over half of the cities, including Cali, the economic benefits exceed USD5.00 for every 379 dollar invested. 380 Wolbachia's costs mostly occur at the beginning, while the health and economic benefits 381 accrue over time. Therefore, the cost effectiveness and economic benefits of Wolbachia 382 increase with longer time horizons. For example, for each dollar invested, the benefit in Cali 383 ranged from USD5.50 at 10 years to USD9.29 at 20 years. Thanks to Colombia's national health

insurance system, the medical care component of these benefits would accrue largely toColombia's public sector.

We used a supplemental method to validate the cost per case of dengue through a supplemental calculation. The consistency between our main (SOAT) and supplemental (macrocosting) approaches lent confidence in our results. The difference in cost per case between our main and supplemental approaches (USD117.50 and USD121.61, respectively) was only 3.5%. Because the SOAT approach provided greater detail, it was our preferred choice. We explored performing additional analyses by tier within Colombia's health system, but inconsistencies precluded doing this reliably with the available data (see Supporting Information S6 Text).

| 393 | Global experience and models raise a caution that Wolbachia may not work in isolated |
|-----|---|
| 394 | circumstances. As one example, in two nearby sites in Vietnam, Wolbachia coverage dropped in |
| 395 | one (Tri Nguyan village) but not in the other (Vinh Luong). Researchers speculated that elevated |
| 396 | temperature in water storage tanks where mosquitoes bred or an interaction with the built |
| 397 | environment may have inhibited Wolbachia replication in the ineffective village[42]. As another |
| 398 | example, in small-scale releases in Malaysia, Wolbachia were not permanently established |
| 399 | because the selected strain (wAlbB) may have been less fit than the wild mosquitoes.[42] |
| 400 | Modeling studies raise the possibility that dengue viruses could become resistant to Wolbachia. |
| 401 | Because of the multiple mechanisms by which Wolbachia inhibit dengue transmission, however, |
| 402 | any such resistance, if any, would likely evolve only slowly.[43] Resistance could be identified by |
| 403 | monitoring and possible corrective actions, such as new Wolbachia strains. |
| 404 | Our very favorable national benefit-cost ratio of 4.68 indicates that our findings are |
| 405 | robust and broadly resistant to such concerns. Our calculations show that the replacement |
| 406 | strategy would remain economically viable nationally even if 10-year efficacy declined by as |
| 407 | much as 78.6%, calculated as $(4.68 - 1)/4.68$. With that large a decline costs of USD1.00 would |
| 408 | generate benefits of USD4.68 x (100.0% - 78.6%) or USD1.00, meaning that the program would |
| 409 | just break even economically. |
| | |

While our benefit-cost ratios compare *Wolbachia* against no dengue control,
policymakers may also wish to consider comparing *Wolbachia* against alternative dengue control
strategies. Among the few trials, an alternative vector control strategy based on communitybased mobilization (*Camino Verde*) proved to be effective but labor intensive and expensive. Its
cost-effectiveness ratios relative to GDP per capita were relatively unfavorable--3.0 in Mexico

| 415 | and 16.9 in Nicaragua.[44] A modeled assessment of screening and vaccination in Colombia with |
|-----|--|
| 416 | the first licensed dengue vaccine (Sanofi's Dengvaxia®) gave cost-effectiveness ratios relative to |
| 417 | GDP per capita ranging from 0.47 (in areas with 90% dengue seropositivity among 9 year-olds) to |
| 418 | 6.72 (with 10% dengue seropositivity).[45] This strategy proved more cost-effective (lower ICER) |
| 419 | as the percentage of nine-year old seropositive individuals in the population increased. |
| 420 | The second dengue vaccine, TAK-003 (Takeda's Qdenga [®]), was licensed by the |
| 420 | The second deligue vaccine, TAK-005 (Takeda's Queliga'), was incensed by the |
| 421 | European Medicines Agency in 2022 and received pre-approval by the World Health |
| 422 | Organization in 2024.[46] Published trial results showed TAK-003 reduced dengue fever cases by |
| 423 | 80% and, unlike Dengvaxia [®] , created no added risk for persons with no prior dengue |
| 424 | infection.[46] While preliminary economic models by the manufacturer projected that Qdenga® |
| 425 | would be cost saving in Puerto Rico[47] and Thailand[48], we could not find any related peer- |
| 426 | reviewed economic studies. Fig 4(B) showed that in the 9 of 11 target municipalities with |
| 427 | dengue incidence of at least 500 per 100,000 population, Wolbachia also proved cost saving. |
| | |
| 428 | As resources for public health interventions are limited, it is informative to compare the |
| 429 | cost-effectiveness of Wolbachia against that of two other public health preventive interventions |
| 430 | in Colombia. First, a year after Colombia had introduced HPV vaccination into its national |
| 431 | vaccination program, [49] a cost-effectiveness analysis reported its ICER was greater than three |
| 432 | times Colombia's then GDP per capita, so HPV was not then considered cost-effective.[50] |
| 433 | Second, a campaign to encourage COVID-19 vaccination among those at highest risk proved cost- |
| 434 | effective [51] by the latest criteria, [40] but not cost saving. |
| 435 | In addition to cost-benefit and cost-effectiveness ratios, policy makers must also |

436 consider the affordability of any proposed program. The first year costs of Wolbachia

437 deployment (\$4.05 per person) represent a notable 0.8% of Colombia's 2019 per capita health 438 expenditure and might appear too expensive if widely implemented at once. However, the 439 program can become more affordable by phasing deployment across parts of a city over multiple 440 years (as happened in Cali) or sequencing successive cities in different years. 441 Several limitations should be acknowledged. The number of dengue cases differs 442 between the RIPS and Suficiencia databases, pointing to inconsistencies and/or under-reporting. 443 Second, differences in numbers of dengue cases treated among different epidemiological 444 models, macro-costing, RIPS, and SIVIGILA creates uncertainty around the estimated healthcare 445 cost offsets. Finally, our adjustments for underreporting and misdiagnosis are based on our 446 panel's expert judgment rather than objective information. However, the extremely favorable

447 benefit-cost ratios in 9 or our 11 target cities indicate that *Wolbachia* deployment would still be

448 highly favorable in those cities.

449 Key strengths also deserve highlighting. First, we believe this is the first economic 450 evaluation of Wolbachia in Colombia, building on the empirical record of efficacy and feasibility 451 from the trial in Indonesia[8] and controlled observational studies in the country.[3, 12-15] 452 Second, we used an empirical method for valuing indirect benefits based on the overall 453 economy.[40] As 64% of Colombia's workers were in the informal sector in 2020 and generally 454 earned less than formal sector workers, [52] this approach is more realistic than applying formal 455 sector wages to indirect costs of all cases, including those not employed or working informally, 456 as was done elsewhere.[19] Third, this study's number of sites (11) substantially exceeds the 457 numbers in previous economic analyses--3 in Indonesia[17] and 7 in Brazil.[19] These multiple 458 sites provided the insight that not only was *Wolbachia* beneficial overall, but it was especially

| 459 | valuable in cities with high dengue incidence. High population density in the release area was |
|-----|--|
| 460 | associated with somewhat more favorable outcomes. As a square kilometer with high dengue |
| 461 | incidence and high population density is one with substantial dengue burden, deploying |
| 462 | Wolbachia in such a location will generate substantial economic value. Conversely, areas with |
| 463 | relatively low incidence and low density would benefit much less; another control strategy may |
| 464 | be preferable.[53] |

465

466 Conclusions

- 467 In conclusion, Wolbachia proved economically beneficial in all 11 target cities and cost saving
- 468 (paying for itself through treatment costs averted) in the 9 target cities with adjusted incidence
- of at least 500 per 100,000 population. In the future, policy makers may have a portfolio of
- 470 options to control dengue. Municipalities with both high incidence of dengue and high
- 471 population density should strongly consider trying to mobilize the resources for Wolbachia
- 472 deployment. Areas with high dengue incidence but low population density should consider
- 473 vaccination. To address the uncertainties around each dengue control technique, some experts
- 474 recommend integrating *Wolbachia*, vaccination, and case management.

475

476 Funding

This work was funded in whole, or in part, by the Wellcome Trust (grant 224459/Z/21/Z) to the
World Mosquito Program (WMP), Monash University (Clayton, VIC, Australia). For the purpose

- 479 of open access, the author has applied a CC BY public copyright license to any Author Accepted
- 480 Manuscript version arising from this submission.

481

482 Author Contributions

- 483 **Donald S. Shepard**: conceptualization; formal analysis; funding acquisition; methodology;
- 484 supervision; writing—review & editing. Samantha R. Lee: data curation; formal analysis;
- 485 writing—original draft, review & editing. Yara A. Halasa-Rappel: data curation; formal analysis;
- 486 writing—original draft, review & editing. **Carlos Rincon Perez**: methodology; data curation;
- 487 formal analysis; writing—review & editing. Arturo Harker Roa: methodology; data curation;
- 488 supervision; writing—review & editing. All authors have read and approved the final version of
- 489 the manuscript. Donald S. Shepard had full access to all of the data in this study and takes
- 490 complete responsibility for the integrity of the data and the accuracy of the data analysis.

491

492 Acknowledgments

- 493 The authors thank Luz Villarreal Salazar for serving on the study's epidemiologic panel, Ivan
- 494 Velez and Patricia Arbelaez Montoya from the WMP Colombia and Reynold Dias and Katherine
- 495 Anders from the global WMP (Australia) for Wolbachia cost data and valuable comments, and
- 496 Clare L. Hurley of Brandeis University for editorial assistance.

497

498 Conflict of Interest Statement

| 499 | All authors received funding from the Wellcome Trust under a grant (224459/Z/21/Z) to the |
|-----|---|
| 500 | World Mosquito Program (WMP), Monash University (Clayton, VIC, Australia), which had no |
| 501 | role in review nor the decision to submit. The direct sponsor (WMP) had the right to review but |
| 502 | authorized submission with no required changes. Donald S. Shepard has received financial |
| 503 | support from Abbott, Inc, Sanofi, and Takeda Vaccines, Inc. in the past 36 months unrelated to |
| 504 | the present study. All other authors declare no other conflicts of interest. |
| 505 | |
| 506 | Data Availability Statement |
| 507 | Data access may be requested from the respective Colombian government agencies. For RIPS, |
| 508 | see https://www.minsalud.gov.co/proteccionsocial/Paginas/rips.aspx. For population, see |
| 509 | https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y- |
| 510 | poblacion/proyecciones-de-poblacion. |
| 511 | |
| 512 | Ethics Statement |
| 513 | This modeling study did not involve any human studies data as it was based entirely on |

aggregate or publicly available anonymous data. These data could not allow any individual to

be identified nor linked with any individual. The research team did not prospectively nor

- retrospectively recruit human participants nor did the team obtain tissues, data, or samples for
- 517 the purposes of this study. The research team did not review existing medical records nor
- 518 archived samples. Therefore, this study was outside the purview of the Committee for
- 519 Protection of Human Studies in Research so ethical approval was not applicable.

520 Transparency Statement

- 521 The lead author Donald S. Shepard affirms that this manuscript is an honest, accurate, and
- 522 transparent account of the study being reported; that no important aspects of the study have
- 523 been omitted; and that any discrepancies from the study as planned (and, if relevant,
- 524 registered) have been explained.
- 525
- 526 **ORCID**
- 527 Donald S Shepard, (ORCID ID: 0000-0003-2187-0593)
- 528 Samantha R. Lee, (ORCID ID: 0000-0002-9225-3077
- 529 Yara A. Halasa-Rappel, (ORCID ID: 0000-0001-6564-1608)
- 530 Carlos Rincon Perez, (ORCID ID: 0009-0004-8721-9159)
- 531 Arturo Harker Roa, (ORCID ID: 0000-0003-2343-1965)

532 References

| 533 | 1. | Castro Rodríguez R, Carrasquilla G, Porra A, Galera-Gelvez K, Lopez Yescas JG, Rueda-Gallardo |
|-----|----|--|
| 534 | | JA. The burden of dengue and the financial cost to Colombia, 2010–2012. Am J Trop Med Hyg |
| 535 | | 2016;94(5):1065-72. doi: 10.4269/ajtmh.15-0280. |
| 536 | 2. | Gutierrez-Barbosa H, Medina-Moreno S, Zapata JC, Chua JV. Dengue infections in Colombia: |
| 537 | | Epidemiological trends of a hyperendemic country. Trop Med Infect Dis. 2020;5(4):156 doi: |
| 538 | | 10.3390/tropicalmed5040156. |
| 539 | 3. | Humphreys G. Tackling mosquito-borne viruses in the Region of the Americas. Bull World Health |
| 540 | | Organ. 2023;101:441–2. doi: 10.2471/BLT.23.020723 |
| 541 | 4. | Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, et al. The |
| 542 | | wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature. |
| 543 | | 2011;476:450–3. doi: 10.1038/nature10355. |
| 544 | 5. | Ross PA, Robinson KL, Yang Q, Callahan AG, Schmidt TL, Axford JK, et al. A decade of stability for |
| 545 | | wMel Wolbachia in natural Aedes aegypti populations. PLoS Pathog. 2022;18(2):e1010256. doi: |
| 546 | | 10.1371/journal.ppat.1010256. |
| 547 | 6. | World Mosquito Program. The World Mosquito Program helps protect communities around the |
| 548 | | world from mosquito-borne diseases. 2023. Available from: |

549 https://www.worldmosquitoprogram.org/.

| 550 | 7. | Soh S, Ho SH, Seah A, Ong J, Dickens BS, Tan KW, et al. Economic impact of dengue in Singapore |
|-----|----|--|
| 551 | | from 2010 to 2020 and the cost-effectiveness of Wolbachia interventions. PLOS Glob Public |

- 552 Health. 2021;1(10):e0000024. doi: 10.1371/journal.pgph.0000024.
- 553 8. Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, et al. Efficacy of
- 554 Wolbachia-infected mosquito deployments for the control of dengue. N Engl J Med.
- 555 2021;384(23):2177–86. doi: 10.1056/NEJMoa2030243.
- 556 9. Dufault SM, Tanamas SK, Indriani C, Ahmad RA, Utarini A, Jewell NP, et al. Reanalysis of cluster
- 557 randomised trial data to account for exposure misclassification using a per-protocol and
- 558 complier-restricted approach. Scientific Reports. 2024;14:Article number 11207. doi:
- 559 10.1038/s41598-024-60896-9.
- 560 10. Pinto SB, Riback TIS, Sylvestre G, Costa G, Peixoto J, Dias FBS, et al. Effectiveness of Wolbachia-
- 561 infected mosquito deployments in reducing the incidence of dengue and other Aedes-borne
- 562 diseases in Niterói, Brazil: A quasi-experimental study. PLoS Negl Trop Dis. 2021;15(7):0009556.
- 563 doi: 10.1371/journal.pntd.0009556.
- 11. dos Santos GR, Durovni B, Saraceni V, Souza Riback TI, Pinto SB, Anders KL, et al. Estimating the
- 565 effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de
- 566 Janeiro, Brazil: a spatiotemporal modelling study. Lancet Infect Dis. 2022;22:1587–95. doi:
- 567 10.1016/S1473-3099(22)00436-4.
- 568 12. Lenharo M. Dengue rates drop after release of modified mosquitoes in Colombia. Nature.
- 569 2023;623:235-6. doi: 10.1038/d41586-023-03346-2.

| 570 | 13. | Velez ID, Santacruz E, Kutcher SC, Duque SL, Uribe A, Barajas J, et al. The impact of city-wide |
|-----|-----|--|
| 571 | | deployment of Wolbachia-carrying mosquitoes on arboviral disease incidence in Medellín and |
| 572 | | Bello, Colombia: study protocol for an interrupted time-series analysis and a test-negative |
| 573 | | design study (version 2). F1000 Research. 2019. doi: f1000research.com/articles/8-1327. |
| 574 | 14. | Velez ID, Tanamas SK, Arbelaez MP, Kutcher SC, Duque SL, Uribe A, et al. Reduced dengue |
| 575 | | incidence following city-wide wMel Wolbachia mosquito releases throughout three Colombian |
| 576 | | cities: Interrupted time series analysis and a prospective case-control study. PLoS Negl Trop Dis. |
| 577 | | 2023;17(11):e0011713. doi: 10.1371/journal.pntd.0011713. |
| 578 | 15. | Velez ID, Uribe A, Barajas J, Uribe S, Ángel S, Suaza-Vasco JD, et al. Large-scale releases and |
| 579 | | establishment of wMel Wolbachia in Aedes aegypti mosquitoes throughout the Cities of Bello, |
| 580 | | Medellín and Itagüí, Colombia. PLoS Negl Trop Dis. 2023;17(11):e0011642. doi: |
| 581 | | 10.1371/journal.pntd.0011642. |
| 582 | 16. | Governorate of Valle del Cauca. This Monday, the 'Wolbachia' project is launched in Yumbo to |
| 583 | | combat dengue. 2023. Available from: |
| 584 | | https://www.valledelcauca.gov.co/publicaciones/78449/este-lunes-se-lanza-en-yumbo-el- |
| 585 | | proyecto-wolbachia-con-el-que-se-busca-combatir-el-dengue/. |
| 586 | 17. | Brady OJ, Kharisma DD, Wilastonegoro NN, O'Reilly KM, Hendrickx E, Bastos LS, et al. The cost- |
| 587 | | effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: A |

588 modelling study. BMC Med. 2020;18(1):186. doi: 10.1186/s12916-020-01638-2.

- 18. Turner HC, Quyen DL, Dias R, Huong PT, Simmons CP, Anders K. An economic evaluation of
- 590 Wolbachia deployments for dengue control in Vietnam. PLoS Negl Trop Dis.
- 591 2023;17(5):e0011356. doi: 10.1371/journal.pntd.0011356.
- 19. Zimmermann IR, Fernandes RRA, da Costa MGS, Pinto M, Peixoto HM. Simulation-based
- 593 economic evaluation of the Wolbachia method in Brazil: A cost-effective strategy for dengue
- 594 control. Lancet Reg Health Am. 2024;35:100783. doi: 10.1016/j.lana.2024.100783.
- 595 20. Shepard DS, Hariharan D, Ratu A, Anders K. Cost-benefit analysis of Wolbachia to control dengue
- 596 in Suva, Fiji and Port Vila, Vanuatu. Annual Conference of the American Society of Tropical
- 597 Medicine and Hygiene (virtual meeting, presentation 1449, Slide 14. 15-19 Nov 2020.
- 598 21. Knerer G, Currie CSM, Brailsford SC. The economic impact and cost-effectiveness of combined
- 599 vector-control and dengue vaccination strategies in Thailand: Results from a dynamic
- transmission model. PLoS Negl Trop Dis. 2020;14:e0008805. doi: 10.1371/journal.pntd.0008805.
- 601 22. Drummond MF, Sculpher MJ, Claxton K, Stoddard GL, Torrance GW. Methods for Economic
- 602 Evaluation of Health Care Programmes. Fourth Edition. New York Oxford; 2015.
- 23. Zeng W, Halasa-Rappel YA, Durand L, Coudeville L, Shepard DS. Impact of a nonfatal dengue
- 604 episode on disability-adjusted life years: A systematic analysis. Am J Trop Med Hyg.
- 605 2018;99(6):1458-65. doi: 10.4269/ajtmh.18-0309.
- 606 24. The World Bank. GDP per capita (current US\$). 2020. Available from:
- 607 https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CO,%20Accessed%207/29/20
- 608

22.

| 609 | 25. | Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: A |
|-----|-----|--|
| 610 | | systematic analysis. Lancet Inf Dis. 2016;16(8):935-41. doi: 10.1016/S1473- 3099(16)00146-8. |
| 611 | 26. | Exchange Rates. US dollar to Colombian peso spot exchange rates for 2016. 2023. Available |
| 612 | | from: https://www.exchangerates.org.uk/USD-COP-spot-exchange-rates-history-2016.html. |
| 613 | 27. | Gobierno de Colombia M. Condiciones de salud para djuste de riesgo de la UPC y mecanismo de |
| 614 | | incentivos para el mejoramiento de la claidad y los resultados en salud [Health conditions for |
| 615 | | UPC risk adjustment and incentive mechanism for quality improvement and health outcomes]. |
| 616 | | 2022. Available from: |
| 617 | | https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/condiciones-salud- |
| 618 | | upc- incentivos-calidad-resultados-salud-2022.pdf. |
| 619 | 28. | Bill and Melinda Gates Foundation. Indirect Cost Guidelines. 2010. Available from: |
| 620 | | https://docs.gatesfoundation.org/documents/historical_indirect_cost_policy.pdf. |
| 621 | 29. | Gobierno de Colombia M. Estructura del gasto en Salud Pública en Colombia, Papeles en Salud. |
| 622 | | Edicion No 17. 2018. Available from: |
| 623 | | https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/PES/estructura-gasto- |
| 624 | | salud- publica-colombia.pdf. |
| 625 | 30. | Ministerio de Salud y Protección Social. Cifras de aseguramiento en salud. 2022. Available from: |
| 626 | | https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx. |
| 627 | 31. | Organization for Economic Cooperation and Development (OECD). Health at a Glance 2021: |
| 628 | | OECD Indicators. Paris: OECD Publishing; 2021. Available from: |
| 629 | | https://doi.org/10.1787/ae3016b9-en. |

- 630 32. Shepard DS, Hodgkin D, Anthony YE. Analysis of Hospital Costs: A Manual for Managers. Geneva,
- 631 Switzerland: World Health Organization; 2000.
- 632 33. Worldometer. Colombia population. 2022. Available from:
- 633 https://www.worldometers.info/world-population/colombia-population/.
- 634 34. Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the economic evaluation of health
- 635 care interventions for priority setting in the health system: an update from WHO CHOICE. Int J
- 636 Health Policy Manag. 2021;10(11):673–7. doi:10.34172/ijhpm.2020.244.
- 637 35. Faria R, Duarte A, McKenna C, Revill P, Cary M, Byford S. Guidelines for the economic evaluation
- of healthcare technologies in Colombia: technical support documents. Bogota: Instituto de
- 639 Evaluación Tecnológica en Salud; 2014. Available from:
- 640 https://www.iets.org.co/Archivos/66/Documentos_tecnicos_en_ingles.pdf.
- 641 36. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and
- 642 health: Investing in health for economic development: Executive summary. 2001. Available
- 643 from: http://www.who.int/iris/handle/10665/42463.
- 644 37. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kienya M-P, et al. Cost-

645 effectiveness thresholds: Pros and cons. Bull World Health Organ. 2016;94:925–30. doi:

- 646 10.2471/BLT.15.164418.
- 647 38. Lasalvia P, Hernández F, Gil-Rojas Y, Rosselli D. Incremental cost-effectiveness analysis of
- 648 tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the
- 649 epidermal growth factor receptor in Colombia. Expert Review of Pharmacoeconomics &
- 650 Outcomes Research. 2021;21(4):821-7. doi: 10.1080/14737167.2020.1779063

| 651 | 39. | Nu Vu A, Hoang MV, Lindholm L, Sahlen KG, Nguyen CTT, Sun S. A systematic review on the |
|-----|-----|--|
| 652 | | direct approach to elicit the demand side cost-effectiveness threshold: Implications for low- and |
| 653 | | middle-income countries. PLoS One. 2024;19(2):e0297450. doi: 10.1371/journal. |
| 654 | 40. | Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the |
| 655 | | efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries |
| 656 | | based on growth in life expectancy and health expenditures. Lancet Glob Health. |
| 657 | | 2023;11(6):e833-e42. doi: 10.1016/S2214-109X(23)00162-6. |
| 658 | 41. | Cao Z, Chen S. Innovative methods of determining health expenditure efficiency are urgently |
| 659 | | needed. Lancet Glob Health. 2023;11(6):e797-e8. doi: 10.1016/S2214-109X(23)00196-1. |
| 660 | 42. | Hien NT, Anh DD, Le NH, Yen NT, Phong TV, Nam VS, et al. Environmental factors influence the |
| 661 | | local establishment of Wolbachia in Aedes aegypti mosquitoes in two small communities in |
| 662 | | central Vietnam. Gates Open Res. 2022;5:147. doi: 10.12688/gatesopenres.13347.2. |
| 663 | 43. | Edenborough KM, Flores HA, Simmons CP, Fraser JE. Using Wolbachia to eliminate dengue: Will |
| 664 | | the virus fight back? J Virol. 2021;95:e02203-20. doi: 10.1128/JVI .02203-20. |
| 665 | 44. | Tschampl CA, Undurraga EA, Ledogar RJ, Coloma J, Legorreta-Soberanis J, Paredes-Solís S, et al. |
| 666 | | Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in |
| 667 | | Nicaragua and Mexico: A cluster randomized controlled trial. Int J Infect Dis. 2020;94:59–67. doi: |
| 668 | | 10.1016/j.ijid.2020.03.026. |
| 669 | 45. | Coudeville L, Baurin N, Shepard DS. The potential impact of dengue vaccination with, and |
| 670 | | without, pre-vaccination screening. Vaccine. 2020;38(6):1363–9. doi: |
| 671 | | 10.1016/j.vaccine.2019.12.012. |

| 672 | 46. | World Health Organization. WHO prequalifies new dengue vaccine. Geneva: WHO; 2024. |
|-----|-----|--|
| 673 | | Available from: https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue- |
| 674 | | vaccine. |
| 675 | 47. | Kaul RR. Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico. |
| 676 | | 2023. Available from: https://stacks.cdc.gov/view/cdc/130011/cdc_130011_DS1.pdf |
| 677 | 48. | Shen J, Kharitonova E, Biswal S, Sharma M, Aballea S, TytuEa A, et al. Disease impact and cost- |
| 678 | | effectiveness of a new dengue vaccine TAK003 in Thailand. International Journal of Infectious |
| 679 | | Diseases. 2023;130(Supplement 2):S141. doi: 10.1016/j.ijid.2023.04.347. |
| 680 | 49. | Pan American Health Organization (PAHO). Colombia Introduces HPV Vaccine into National |
| 681 | | Immunization Schedule. 2012. Available from: |
| 682 | | https://www3.paho.org/hq/index.php?option=com_content&view=article&id=7358:2012. |
| 683 | 50. | Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW. Cost- |
| 684 | | effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a |
| 685 | | societal perspective in Colombia. PloS One. 2013;8(11):e80639. doi: |
| 686 | | 10.1371/journal.pone.0080639. |
| 687 | 51. | Morales-Zamora G, Espinosa O, Puertas E, Fernández JC, Hernández J, Zakzuk V, et al. Cost- |
| 688 | | effectiveness analysis of strategies of COVID-19 vaccination in Colombia: Comparison of high- |
| 689 | | risk prioritization and no prioritization strategies with the absence of a vaccination plan. Value |
| 690 | | Health Reg Issues. 2022;31:101-10. doi: 10.1016/j.vhri.2022.04.004. |
| 691 | 52. | Danish Trade Union Development Agency, Norwegian Confederation of Trade Unions. Labour |
| 692 | | Market Profile Colombia – 2023/2024. Copenhagen: Ulandssekretariatet; 2023. Available from: 40 |


- 693 https://www.ulandssekretariatet.dk/wp-content/uploads/2023/06/LMP-Colombia-2023-
- 694 final.pdf.
- 695 53. Ooi EE, Wilder-Smith A. Externalities modulate the effectiveness of the Wolbachia release
- 696 programme. Lancet Inf Dis. 2022;22(11):1518-9. doi: 10.1016/S1473-3099(22)00497-2.

| 698 | Figure Legends |
|-----|--|
| 699 | Fig 1. Economic benefits of Wolbachia by component and time horizon |
| 700 | |
| 701 | Fig 2. Gross and net healthcare costs of Wolbachia by component and time horizon |
| 702 | |
| 703 | Fig 3. Program impacts (DALYs and benefit-cost ratios) in Cali by time horizon |
| 704 | Note: DALYs denote disability adjusted life years |
| 705 | |
| 706 | Fig 4. Estimated benefit-cost ratios by city with a 10-year horizon |
| 707 | |
| 708 | |
| 709 | Supporting Information |
| 710 | S1 Table. Input data for target cities |
| 711 | S2 Text: Macro-costing approach |
| 712 | S3 Table. Macro-costing approach to estimate the average cost of an outpatient visit and hospitalization |

713 (monetary amounts in 2020 USD)

- 54 Table. Health care cost of dengue cases by type of dengue diagnosis and setting using macro-costing
- 715 (amounts in 2019-2020 USD)
- 716 S5 Table. Cost of dengue case by dengue type (Tarifa SOAT for reported), 2019-20 USD
- 717 S6 Text.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.






Figure 1




Figure 3




Figure 4